BRAND NAME:

Scilina-M XR

GENERIC NAME:

Empagliflozin + Linagliptin + Metformin HCl

THERAPEUTIC SEGMENT:

Antidiabetic

INDICATIONS:

Scilina-M XR is a combination of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease.

BRIEF DESCRIPTION:

Empagliflozin + Linagliptin + Metformin XR is an orally bioavailable, triple-combination antidiabetic therapy that targets multiple pathophysiological pathways of type 2 diabetes mellitus (T2DM). Empagliflozin, a sodium-glucose co-transporter-2 (SGLT2) inhibitor, reduces renal glucose reabsorption, promoting glycosuria and improving glycemic control while also offering cardiovascular and renal benefits. Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances incretin hormone activity, increasing insulin secretion and reducing glucagon levels in a glucose-dependent manner. Metformin XR, a biguanide, decreases hepatic glucose production and improves insulin sensitivity. This combination provides complementary mechanisms for sustained glycemic control with a reduced risk of hypoglycemia.

DOSAGE FORM:

Tablets

5mg+2.5mg+1000mg

10mg+5mg+1000mg

12.5mg+2.5mg+1000mg

25mg+5mg+1000mg